- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
441
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
441 companies
Centessa Pharmaceuticals
Market Cap: US$3.2b
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
CNTA
US$23.01
7D
0.2%
1Y
46.8%
Prestige Consumer Healthcare
Market Cap: US$3.1b
Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
PBH
US$62.72
7D
-2.2%
1Y
-12.1%
Mineralys Therapeutics
Market Cap: US$3.0b
A clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
MLYS
US$38.51
7D
-3.4%
1Y
221.2%
NewAmsterdam Pharma
Market Cap: US$3.0b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$26.76
7D
9.3%
1Y
75.6%
Perrigo
Market Cap: US$2.9b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$20.76
7D
-2.9%
1Y
-19.0%
Xenon Pharmaceuticals
Market Cap: US$2.9b
A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.
XENE
US$36.59
7D
-0.3%
1Y
-3.9%
Apellis Pharmaceuticals
Market Cap: US$2.9b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$22.22
7D
-5.0%
1Y
-25.6%
Indivior
Market Cap: US$2.9b
Develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
INDV
US$22.81
7D
-0.3%
1Y
129.9%
CG Oncology
Market Cap: US$2.8b
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
CGON
US$36.48
7D
-6.0%
1Y
-0.8%
Ultragenyx Pharmaceutical
Market Cap: US$2.8b
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
RARE
US$27.82
7D
-4.4%
1Y
-49.6%
Veracyte
Market Cap: US$2.7b
Operates as a diagnostics company in the United States and internationally.
VCYT
US$32.68
7D
2.7%
1Y
-2.0%
Kiniksa Pharmaceuticals International
Market Cap: US$2.7b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$35.51
7D
-1.1%
1Y
48.2%
Supernus Pharmaceuticals
Market Cap: US$2.6b
A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$47.10
7D
5.1%
1Y
57.3%
Amicus Therapeutics
Market Cap: US$2.6b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$8.32
7D
-1.9%
1Y
-22.4%
Catalyst Pharmaceuticals
Market Cap: US$2.4b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$19.13
7D
-6.2%
1Y
-4.1%
ImmunityBio
Market Cap: US$2.4b
A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
IBRX
US$2.46
7D
-13.7%
1Y
-36.9%
Belite Bio
Market Cap: US$2.3b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$70.01
7D
-4.4%
1Y
49.4%
Celcuity
Market Cap: US$2.3b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$51.94
7D
-5.6%
1Y
264.7%
Ocular Therapeutix
Market Cap: US$2.2b
A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
OCUL
US$12.24
7D
-3.7%
1Y
39.4%
Travere Therapeutics
Market Cap: US$2.2b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$24.61
7D
1.7%
1Y
63.6%
Disc Medicine
Market Cap: US$2.2b
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
IRON
US$62.50
7D
-0.2%
1Y
30.1%
Agios Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
AGIO
US$36.61
7D
-3.5%
1Y
-23.8%
Arcutis Biotherapeutics
Market Cap: US$2.1b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$16.73
7D
-5.5%
1Y
82.6%
Denali Therapeutics
Market Cap: US$2.0b
A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
DNLI
US$13.43
7D
1.9%
1Y
-54.1%
Adaptive Biotechnologies
Market Cap: US$2.0b
A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
ADPT
US$13.12
7D
-4.7%
1Y
167.8%
ANI Pharmaceuticals
Market Cap: US$1.9b
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
ANIP
US$94.99
7D
-0.4%
1Y
65.8%
Liquidia
Market Cap: US$1.9b
A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
LQDA
US$22.45
7D
-9.0%
1Y
121.4%
Sarepta Therapeutics
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
SRPT
US$17.71
7D
-4.4%
1Y
-85.8%
Harrow
Market Cap: US$1.8b
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
HROW
US$46.15
7D
1.7%
1Y
4.3%
Immunocore Holdings
Market Cap: US$1.7b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$34.08
7D
2.0%
1Y
10.8%
Aurinia Pharmaceuticals
Market Cap: US$1.7b
A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
AUPH
US$12.88
7D
4.7%
1Y
78.9%
Vera Therapeutics
Market Cap: US$1.7b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$26.14
7D
6.5%
1Y
-41.8%
MannKind
Market Cap: US$1.6b
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
MNKD
US$5.33
7D
-1.1%
1Y
-16.6%
BioCryst Pharmaceuticals
Market Cap: US$1.6b
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
BCRX
US$7.65
7D
-3.9%
1Y
0.9%
Twist Bioscience
Market Cap: US$1.6b
Manufactures and sells synthetic DNA-based products.
TWST
US$26.75
7D
-4.3%
1Y
-43.2%
Viridian Therapeutics
Market Cap: US$1.6b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$19.08
7D
-2.8%
1Y
-17.3%